Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory And Policy News, In Brief

Executive Summary

PhRMA Names Top Gov't Relations Exec

You may also be interested in...



Greater Health Information Exchange In Next Phase Of HIT Meaningful Use

More stringent requirements for health information exchange, as well as clinical decision support, will be a part of the next phase of requirements to demonstrate the meaningful use of health information technology, HHS' David Blumenthal said.

GDUFA Timetable Unclear, But Negotiations Will Begin With Lots Of Agreement - Except For Mylan

Coalition and GPhA expect to be on the same page at FDA public meeting, but Mylan proposes alternative user fee structure based on establishment fees.

FDA Launches New System To Track Performances of Its Offices

As part of its transparency initiative, agency has introduced FDA-Track, which reports actions taken by more than 100 agency offices.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel